Rinki Kapoor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rinki Kapoor has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Annelise E. Barron
Stanford University Schools of Medicine and Engineering
2 shared publications A.E. Barron
1 shared publicationAlfred M. Spormann
Civil and Environmental Engineering, Stanford University, Stanford, California 94305
1 shared publicationAnn M. Czyzewski
Department of Chemical and Biological Engineering, Northwestern University, Evanston, Illinois 60208
1 shared publicationAnnelise E. Barron
1 shared publication- Christopher H. Contag
Michigan State University
1 shared publication
Latest Publications
- 1 August 2011
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 17 (25) , 2732-2747
Peptoids: Bio-Inspired Polymers as Potential Pharmaceuticals
Peptoids are a developing class of peptide-like oligomers originally invented for drug discovery in the early 1990s. While peptides hold great promise for therapeutic applications, current development of peptide-based pharmaceuticals is hindered by their potential for misfolding and aggregation, and particularly, for rapid in vivo degradation post-administration. Researchers have investigated alternative peptide-like constructs that may be able to circumvent such complications. Peptoids comprise a peptide-based backbone and Nsubstituted glycines for side chain residues, resulting in complete protease-resistance. Synthesis of peptoid sequences up to 50 units in length allows for controlled sequence composition and incorporation of diverse side chain chemistries. Though the landscape of peptoid structure is not clearly defined, secondary, tertiary, loop, turn, and random structures have been identified. As protease-resistant isomers of peptides, peptoids are being developed as versatile molecular tools in biochemistry and biophysics, and are becoming attractive candidates for therapeutic and diagnostic applications. Peptoids have thus far demonstrated bioactivity as protein mimics and as replacements for small molecule drugs. In this review, we discuss the most recent advances in peptoid research on the therapeutic front in the last few years, including in vitro and in vivo studies in the fields of lung surfactant therapy, antimicrobial agents, diagnostics, and cancer. We particularly focus on the biophysical activity of lipid-associated peptoids and their potential therapeutic applications.
- 1 August 2011
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 17 (25) , 2732-2747
Peptoids: Bio-Inspired Polymers as Potential Pharmaceuticals
Peptoids are a developing class of peptide-like oligomers originally invented for drug discovery in the early 1990s. While peptides hold great promise for therapeutic applications, current development of peptide-based pharmaceuticals is hindered by their potential for misfolding and aggregation, and particularly, for rapid in vivo degradation post-administration. Researchers have investigated alternative peptide-like constructs that may be able to circumvent such complications. Peptoids comprise a peptide-based backbone and Nsubstituted glycines for side chain residues, resulting in complete protease-resistance. Synthesis of peptoid sequences up to 50 units in length allows for controlled sequence composition and incorporation of diverse side chain chemistries. Though the landscape of peptoid structure is not clearly defined, secondary, tertiary, loop, turn, and random structures have been identified. As protease-resistant isomers of peptides, peptoids are being developed as versatile molecular tools in biochemistry and biophysics, and are becoming attractive candidates for therapeutic and diagnostic applications. Peptoids have thus far demonstrated bioactivity as protein mimics and as replacements for small molecule drugs. In this review, we discuss the most recent advances in peptoid research on the therapeutic front in the last few years, including in vitro and in vivo studies in the fields of lung surfactant therapy, antimicrobial agents, diagnostics, and cancer. We particularly focus on the biophysical activity of lipid-associated peptoids and their potential therapeutic applications.
- 1 June 2011
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (6) , 3058-3062
Efficacy of Antimicrobial Peptoids against Mycobacterium tuberculosis
Tuberculosis is a leading cause of death worldwide. Resistance of Mycobacterium to antibiotics can make treatments less effective in some cases. We tested selected oligopeptoids—previously reported as mimics of natural host defense peptides—for activity against Mycobacterium tuberculosis and assessed their cytotoxicity. A tetrameric, alkylated, cationic peptoid (1-C13 4mer ) was most potent against M. tuberculosis and least cytotoxic, whereas an unalkylated analogue, peptoid 1 4mer , was inactive. Peptoid 1-C13 4mer thus merits further study as a potential antituberculosis drug.
- 1 June 2011
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (6) , 3058-3062
Efficacy of Antimicrobial Peptoids against Mycobacterium tuberculosis
Tuberculosis is a leading cause of death worldwide. Resistance of Mycobacterium to antibiotics can make treatments less effective in some cases. We tested selected oligopeptoids—previously reported as mimics of natural host defense peptides—for activity against Mycobacterium tuberculosis and assessed their cytotoxicity. A tetrameric, alkylated, cationic peptoid (1-C13 4mer ) was most potent against M. tuberculosis and least cytotoxic, whereas an unalkylated analogue, peptoid 1 4mer , was inactive. Peptoid 1-C13 4mer thus merits further study as a potential antituberculosis drug.
- 1 June 2011
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (6) , 3054-3057
Antimicrobial Peptoids Are Effective against Pseudomonas aeruginosa Biofilms
The resistance of biofilms to conventional antibiotics complicates the treatment of chronic cystic fibrosis (CF). We investigated the effects of peptoids, peptides, and conventional antibiotics on the biomass and cell viability within Pseudomonas aeruginosa biofilms. At their MICs, peptoids 1 and 1-C13 4mer caused maximum reductions in biomass and cell viability, respectively. These results suggest that peptoids of this class could be worth exploring for the treatment of pulmonary infections occurring in CF patients.
- 1 June 2011
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (6) , 3054-3057
Antimicrobial Peptoids Are Effective against Pseudomonas aeruginosa Biofilms
The resistance of biofilms to conventional antibiotics complicates the treatment of chronic cystic fibrosis (CF). We investigated the effects of peptoids, peptides, and conventional antibiotics on the biomass and cell viability within Pseudomonas aeruginosa biofilms. At their MICs, peptoids 1 and 1-C13 4mer caused maximum reductions in biomass and cell viability, respectively. These results suggest that peptoids of this class could be worth exploring for the treatment of pulmonary infections occurring in CF patients.
- Open Access
- 1 January 2010
- Published by Elsevier in Biophysical Journal
- Vol. 98 (3) , 277a-277
Cationic, Helical Antimicrobial Peptoids with Biomimetic Antimicrobial Activity
- 1 January 2010
- Published by Elsevier in Biophysical Journal
- Vol. 98 (3) , 277a-277
Open AccessCationic, Helical Antimicrobial Peptoids with Biomimetic Antimicrobial Activity